Overall CHF supports the recommended priorities and actions and welcomes the commitment to further consultation with children, families and young people as implementation plans are developed and operationalised. We welcome ARACY’s proposed life course approach: it is important that the plan...
On 1 April 2019, private health insurance begins the most extensive changes in recent years. The aim of this Healthy Cover guide is to provide an easy-to-understand overview of the changes and point consumers to more detailed information that will help them work through the changes to assess...
We are pleased to provide a submission supporting the continuation and strengthening of the Tobacco Control Regulations in Australia. Since the...
Response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2
CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased...
Response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2
CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased...
CHF appreciates the opportunity to provide a comment to the Therapeutic Goods Administration (TGA) proposal to introduce a Unique Device Identification (UDI) system for medical devices in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s...
Consumers Health Forum of Australia (CHF) appreciates the opportunity to provide feedback in response to the proposed Standard for Informed Financial Consent (the Standard), developed by the Cancer Council, Breast Cancer Network Australia, CanTeen and Prostate Cancer Foundation.
CHF...
The CHF supports the reintroduction of pills into the scope of the remade Order. The omission of these from the current Order is an unfortunate regulatory oversight. Consumers implicitly trust the regulatory system to ensure any product made available to them undergoes rigorous assessment of...
We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming...
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind.
CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not...